NLRP3 and Parkinson disease: In a PD model, the drug elevated striatal DA by activating tyrosine hydroxylase [28] to lend credence to the present ability of CLZ to enhance the cortical monoamine content that acts as the fourth reason for NLRP3 inflammasome inhibition.